Pfizer has been asked to explain the circumstances of a patient support programme by Australia’s Therapeutic Goods Administration.

Under the programme, Pfizer Australia pays pharmacists $7 for each patient prescribed one of nine selected Pfizer drugs who is then signed up for the support programme.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The pharmacist is then expected to forward on the patient’s contact information to Pfizer, allowing the company to communicate directly with the consumer to offer them information and advice pertaining to their condition.

The Therapeutic Goods Administration is investigating to see whether this exchange of information breaches the Therapeutic Goods Act, which bans the marketing of prescription drugs supplied under the nation’s Pharmaceutical Benefits Scheme.

At least 18 similar programmes are currently in existence between pharmaceutical companies and Australia’s Pharmacy Guild.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact